問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Cathay General Hospital

Recruiting

List

27Cases

2025-09-30 - 2032-03-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2023-06-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
19Sites

Recruiting19Sites

2019-06-01 - 2023-12-31

Phase II

Completed
A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects With Systemic Lupus Erythematosus

  • Condition/Disease

    Systemic Lupus Erythematosus (SLE)

  • Test Drug

    BMS-986165

Participate Sites
4Sites

Recruiting4Sites

2024-08-26 - 2026-07-23

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2025-04-01 - 2026-03-31

Others

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2024-07-01 - 2027-12-31

Phase III

Active
Studies of Heart & Kidney Protection with BI 690517 in combination with empagliflozin: A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease

  • Condition/Disease

    chronic kidney disease

  • Test Drug

    placebo ‧ BI 690517 Empagliflozin

Participate Sites
23Sites

Recruiting23Sites

2023-05-10 - 2025-04-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting6Sites

Terminated1Sites

2022-06-01 - 2024-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Not yet recruiting4Sites

Recruiting8Sites

2024-06-01 - 2028-05-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2020-03-01 - 2021-10-13

Phase III

An Open-Label, Randomized, Parallel-Group, Multi-Site Study to Evaluate the Efficacy and Safety of Azelastine HCl-Fluticasone propionate Nasal Spray 137-50 mcg/spray in Perennial Allergic Rhinitis patients

  • Condition/Disease

    Perennial Allergic Rhinitis

  • Test Drug

    Azelastine HCl及Fluticasone propionate 137/50

Participate Sites
5Sites

Recruiting5Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB